Hunan Er-Kang Pharmaceutical Co., Ltd: history, ownership, mission, how it works & makes money

Founded in October 2003 and now listed on Shenzhen (300267.SZ), Hunan Er-Kang Pharmaceutical has grown from a domestic excipient and API maker into a global player with an ambitious footprint-most notably a Cambodian industrial park built with an investment of 2 billion yuan spanning 2,000 acres and employing nearly 1,000 Cambodian-Chinese staff-and today it reports a trailing twelve-month revenue of 1.29 billion yuan as of September 30, 2025 while navigating financial headwinds including a 2024 net loss of about 373.37 million yuan; yet the market still places its value at roughly 6.97 billion yuan (market cap as of October 3, 2025) amid a product portfolio of 127 excipients, 73 APIs, 282 finished-drug approvals, over 90 patents for its starch-based plant capsule, exports to nearly 40 countries, designation as a National Pharmaceutical Excipient Engineering Technology Research Center and multiple national honors-data points that set the stage for a closer look at its history, ownership, mission, operations (annual capacities like 11,000 tons of caffeine, 1,000 tons of folic acid and 30,000 tons of sodium citrate in Cambodia), revenue drivers across excipients, APIs and finished products, and its strategy to scale in Asia and Africa as the regional pharmaceutical market expands.

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ): Intro

• Established: October 2003
• Listed ticker: 300267.SZ (Shenzhen Stock Exchange)
• Core activities: Pharmaceutical excipients, APIs, finished drug products; R&D and technology platforms

• Excipients: pharmaceutical-grade carriers and formulation aids used by generic and branded drug makers
• APIs: production of small-molecule active ingredients for domestic and export customers
• Finished products: tablets, capsules and other formulations sold through distributors and hospitals
• R&D services: formulation development, scale-up, and regulatory support

• Direct product sales - excipients, APIs and finished drugs to manufacturers, distributors and healthcare institutions
• Contract manufacturing and toll processing for third-party pharmaceutical firms
• Export sales from both China-based facilities and the Cambodia industrial park
• Licensing, technology services and partnerships leveraging the National Pharmaceutical Excipient Engineering Technology Research Center

• Manufacturing footprint: domestic plants plus a large overseas production/industrial park in Cambodia (~2,000 acres)
• Workforce: includes nearly 1,000 Cambodian-Chinese staff at the Cambodia site (2013 figure)
• R&D capabilities: recognized national engineering research center for excipients; part of national programs to secure key excipient varieties

• Publicly traded company (300267.SZ) with a board of directors and typical Chinese listed-company governance structure
• Shareholder mix: institutional investors, public float and company insiders/founders (typical for Shenzhen-listed pharmas)

• Vertical integration across excipients → APIs → finished formulations improves margin capture and supply security
• National-level recognition (brand project, IP advantages, research center) supports market credibility and regulatory positioning
• Large overseas manufacturing investment (~2 billion yuan in Cambodia) diversifies production capacity and cost base

• Mission Statement, Vision, & Core Values (2026) of Hunan Er-Kang Pharmaceutical Co., Ltd.

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ): History

• Public listing: Shenzhen Stock Exchange, ticker 300267.SZ.
• Employees: 1,453 as of December 31, 2024 (down 44 from prior year).
• Market cap: ~6.97 billion yuan (as of October 3, 2025; +21.58% year-over-year).
• Enterprise value: 6.60 billion yuan (as of October 3, 2025).
• Share price: 3.51 yuan (December 11, 2025); 52-week range 2.14-4.83 yuan.
• TTM revenue: 1.29 billion yuan (trailing twelve months ending September 30, 2025).
• Q3 2025 growth: revenue growth of 39.32% year-over-year.

Ownership Structure

• Major shareholders include institutional investors, company insiders and public float on Shenzhen Stock Exchange.
• As a listed entity, ownership is distributed across retail and institutional holders, with regulatory disclosures governing significant stakes.

Mission

• The company aims to develop, manufacture and supply safe, effective pharmaceutical products to meet clinical needs in China and selective export markets.
• See the detailed corporate mission and values: Mission Statement, Vision, & Core Values (2026) of Hunan Er-Kang Pharmaceutical Co., Ltd.

How It Works & Makes Money

• Manufacturing: production of active pharmaceutical ingredients (APIs), finished dosage forms and sterile injectables in owned facilities - revenue generated through product sales to hospitals, distributors and wholesalers.
• R&D and product lifecycle: in-house development and incremental reformulations allow higher-margin proprietary products alongside commoditized generic lines.
• Sales channels: direct hospital procurement, distributor networks and bidding processes for public hospitals drive volumes; pricing and reimbursement policies affect margins.
• Cost structure: manufacturing scale, raw-material sourcing and capacity utilization determine gross margin; R&D and regulatory compliance are ongoing operating expenses.
• Financial performance drivers: recent strong top-line growth (TTM revenue 1.29 billion yuan; Q3 2025 +39.32%) coupled with market-cap expansion (≈6.97 billion yuan) underpin investor valuation.

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ): Ownership Structure

• Committed to medicine and food safety, focusing on high-quality pharmaceutical products and excipients.
• Pioneer in pharmaceutical excipients and standards-setting; first to industrialize starch capsules in China.
• Innovation-driven with emphasis on IP protection, regulatory compliance and global supply reliability.

• Manufactures and sells pharmaceutical excipients, APIs and finished drug products to domestic pharmaceutical firms, distributors and export markets.
• Licenses proprietary capsule and excipient technologies and supplies contract manufacturing for third parties.
• Generates recurring revenue from a broad portfolio of excipients and IR/DRUG formulations protected by patents and regulatory approvals.

• Listed company on Shenzhen (300267.SZ) with a mix of institutional investors, retail free float and strategic shareholders involved in management and operations.
• Governance emphasizes R&D investment, quality systems and regulatory compliance to support export and domestic supply chains.

• Named a National Torch Program Key High-tech Enterprise.
• Included in the Xinhua News Agency National Brand Project.
• Recognized domestically as an architect of national pharmaceutical excipient standards and a leader in starch capsule industrialization.

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ): Mission and Values

• Headquarters: Changsha, Hunan Province, China.
• Cambodian industrial park: ~2,000 acres; nearly 1,000 Cambodian-Chinese staff employed on-site.
• Manufacturing footprint: multiple state-of-the-art production workshops with high annual capacities.
• Strategic distribution: partnerships with international distributors, including a major Southeast Asia distributor agreement signed in 2023.
• Regulatory investment: ~USD 15 million invested in the last fiscal year to meet FDA and EMA requirements for new product launches and formulation adaptations.

• API and excipient manufacturing (high-volume commodities: caffeine, sodium citrate, folic acid).
• Finished-dose products adapted for regulated markets (FDA/EMA-compliant formulations).
• Contract manufacturing and toll processing for regional partners.
• Distribution partnerships to reach Southeast Asian and international markets.

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ): How It Works

• Core product lines: pharmaceutical excipients, APIs, finished drug products (oral solids, injections, topical formulations).
• Revenue channels: direct sales to hospitals and distributors, B2B bulk sales to drug manufacturers, registered finished-product sales under its own labels.
• Value chain activities: R&D and formulation development, GMP manufacturing, quality control, regulatory registration and post-market pharmacovigilance.

• Excipients and APIs: higher-volume, lower-margin B2B contracts that provide steady recurring cash flow.
• Finished drugs: higher-margin finished formulations sold through distributors and medical institutions; pricing influenced by NRDL (National Reimbursement) status and hospital tenders.
• Contract manufacturing and toll processing: capacity utilization contributes incremental margin and absorbs fixed-cost base.

• Raw material and API precursor costs: primary variable cost; volatility affects margins.
• Manufacturing fixed costs: plant depreciation, GMP compliance, and quality systems; scale and utilization key to diluting fixed cost per unit.
• R&D and regulatory expenses: one-time and ongoing costs for new registrations and life-cycle maintenance.
• Sales & distribution: tendering, hospital listing, and distributor margins influence realized prices for finished products.

• Improving plant utilization and production mix toward higher-margin finished formulations.
• Cost optimization in procurement of API precursors and excipient raw materials.
• Advancing pipeline registrations to expand reimbursed products and hospital access.
• Selective contract manufacturing to fill excess capacity and stabilize cash flow.

• Ownership composition: a mix of institutional investors, retail holders and company insiders (publicly listed on Shenzhen, 300267.SZ).
• Governance emphasis: GMP compliance, quality assurance, and regulatory alignment for domestic market expansion.
• Strategic priorities: scale manufacturing for excipients/APIs, build finished-product portfolio, and pursue tender/NRDL access where feasible.

• Mission focus: reliable production of essential pharmaceutical inputs and accessible finished medicines to support patient care and health-system needs.
• Values: quality, compliance, and industrial-scale supply reliability.

Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ): How It Makes Money

• Product sales: pharmaceutical excipients (starch-based capsules, film formers, fillers, binders) sold to manufacturers and contract packagers.
• Export revenue: direct exports and distributor sales to nearly 40 countries and regions worldwide.
• Distribution & licensing: agreements with international distributors (including a 2023 Southeast Asia distribution agreement opening access to >600 million potential consumers).
• Value-added services: technical support, formulation services and custom excipient development for clients.
• R&D-driven premium products: higher-margin specialty excipients and patented formulations leveraged by its high‑tech enterprise status.